Welcome to our dedicated page for Vyome Holdings SEC filings (Ticker: HIND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vyome Holdings, Inc. filings document the public-company record of a Nasdaq-listed clinical-stage biopharmaceutical issuer. Its disclosures cover operating and financial results, Regulation FD presentation materials, material definitive agreements, clinical and regulatory program information, and capital-structure matters involving its common stock.
Proxy statements and Form 8-K reports describe shareholder votes, director elections, equity incentive plan matters, auditor ratification, executive-compensation advisory votes, and charter amendments, including a reduction in authorized common shares. The filings also provide formal records of governance actions and risk-related disclosure categories relevant to Vyome’s pharmaceutical and biotechnology operations.
Vyome Holdings, Inc (HIND) reported that director Mohanjit Jolly received a grant of stock options on September 1, 2026. The grant covers 120,000 options to purchase Vyome common stock at an exercise price of $2.17 per share under the company’s 2025 Equity Incentive Plan. The options are fully vested and expire on September 1, 2036, bringing Jolly’s directly held derivative position to 137,833 options after the grant. No Rule 10b5-1 trading plan is reported for this award.
Vyome Holdings, Inc (HIND) had its Chief Financial Officer, Leonard Jerry, file an initial statement of beneficial ownership on Form 3. The filing lists him as an officer but does not report any equity transactions or holdings, indicating no reportable beneficial ownership positions at the time of the filing.
Vyome Holdings, Inc. (HIND) reported leadership changes in its finance organization. The board appointed Jerry Leonard as Chief Financial Officer under a Consulting Agreement with ClearbridgeCFO, LLC, effective September 1, 2026
Vyome will pay ClearBridge a consulting fee of $15,000 per month under an initial one-year term that automatically renews for successive 12‑month periods, subject to termination rights. Robert Dickey notified the board of his voluntary resignation as Interim Chief Financial Officer, effective August 31, 2026, and the company’s consulting agreement with Foresite Advisors, LLC will be deemed terminated the same date.
Vyome Holdings, Inc. (HIND) reported second quarter 2026 results and provided a corporate update centered on its lead VT-1953 program and an expanded immuno-inflammatory pipeline. For the six months ended June 30, 2026, revenue was $58,546 compared with $248,535 in the prior-year period, while operating expenses rose to $2,020,809 from $701,839, leading to an operating loss of $1,992,506 versus $523,185. Net loss was $1,705,204 compared with $602,732 a year earlier.
The balance sheet shows higher liquidity and equity: cash and cash equivalents were $7,887,510 as of June 30, 2026 versus $4,982,333 at December 31, 2025, and total stockholders’ equity increased to $7,311,706 from $3,762,017 as liabilities declined to $1,864,656 from $2,735,160. Management highlights advancement of VT-1953 toward pivotal development, addition of two selective JAK inhibitor assets through an Impetis agreement, and emphasizes a capital structure with no debt, no preferred stock, and no toxic financing instruments.
Vyome Holdings, Inc. (HIND) is a clinical-stage specialty pharmaceutical company focused on immune‑inflammatory and rare diseases, reporting two segments: a small India-based pharmaceutical revenue stream and a larger biotechnology R&D operation. For the six months ended June 30, 2026, revenue was $58,546, down from $248,535 in 2025, generating gross profit of $28,303.
Operating expenses rose sharply to $2,020,809, driven by research and development of $1,173,128 and selling, general and administrative expenses of $842,466. The company recorded other income, net, of $287,302, mainly interest income, resulting in a net loss of $1,705,204 versus $602,732 a year earlier. Operating cash outflow was $2,339,676.
Cash and cash equivalents increased to $7,887,510 from $4,982,333, primarily from an at‑the‑market equity program that raised $5,285,868. There is no debt outstanding; total liabilities were $1,864,656 and stockholders’ equity was $7,311,706, with 7,018,528 common shares outstanding. The pipeline includes lead asset VT‑1953 for malignant fungating wounds (Phase II completed, orphan drug designation application filed and FDA pre‑IND feedback received), a Phase III‑ready acne program VB 1953, and newly in‑licensed JAK inhibitor assets. Vyome also disclosed an Indian GST tax refund dispute with a potential demand of about $750,000, which it is contesting and for which no liability has been recorded. Management believes current resources and an equity facility can fund operations for at least 12 months while it continues to seek additional financing.
Vyome Holdings reported first quarter 2026 results and highlighted progress on its clinical pipeline and balance sheet. The company is advancing VT-1953 for malignant fungating wounds and has submitted an application to the FDA for orphan drug designation and proposals for next-stage development planning.
Cash and cash equivalents were $8.8 million as of March 31, 2026, up from $5.0 million at December 31, 2025, with total assets increasing to $10.2 million. Total stockholders’ equity rose to $8.0 million from $3.8 million, and management emphasized having no debt, no preferred stock, and no toxic financing instruments.
For the quarter ended March 31, 2026, Vyome generated revenue of $31,591, down from $198,581 a year earlier, and recorded a net loss of $985,521 versus $293,974 in the prior-year period, driven by higher operating expenses of $1.15 million. The company plans a conference call and webcast on June 3, 2026, to discuss these results.
Vyome Holdings, Inc. reports results for the three months ended March 31, 2026, showing a small revenue base and higher investment in R&D. Revenue was $31,591, down from $198,581 a year earlier, entirely from its Indian dermatology products and royalties.
The company recorded a net loss of $985,521, compared with $293,974 in the prior-year quarter, driven mainly by increased research and development expense of $666,405 and selling, general and administrative costs of $477,575. Operating cash outflow was $1,435,964.
Liquidity improved after an at-the-market equity program, which raised $5,288,868 of gross proceeds, lifting cash and cash equivalents to $8,795,783 at March 31, 2026. Common shares outstanding rose to 7,018,528. Vyome remains a clinical-stage company focused on immune-inflammatory and rare disease programs, including lead topical candidate VT-1953.
Vyome Holdings, Inc. reported results of its 2026 annual stockholder meeting and a charter change. Stockholders approved an amendment to reduce common stock authorized for issuance from 300,000,000 to 50,000,000 shares, leaving total authorized capital at 60,000,000 shares, including 10,000,000 preferred shares.
Two Class II directors, Venkat Nelabhotla and John Tincoff, were elected to serve until the 2029 annual meeting. Stockholders also ratified Kreit & Chiu CPA LLP as independent auditors for the year ending December 31, 2026 and approved, on a non-binding advisory basis, the compensation of named executive officers.
Vyome Holdings, Inc. is asking stockholders to approve four main items at its 2026 annual meeting on April 24 in New York. Investors will vote to re-elect Venkat Nelabhotla and John Tincoff as Class II directors, approve an advisory “say‑on‑pay” for named executive compensation, and ratify Kreit & Chiu CPA LLP as independent auditor for 2026.
A key proposal would amend the charter to cut authorized common stock from 300,000,000 to 50,000,000 shares. The board says this better matches capital needs, reduces potential dilution concerns and may lower Delaware franchise tax from about $155,000 to about $25,000 for tax years 2026 and 2027. As of March 2, 2026, 7,018,528 common shares were outstanding, with additional shares tied to options, plan reserves and warrants.
The proxy details board structure, committee roles—including a specialized AI Committee—beneficial ownership, and 2025 executive pay, including $478,711 in total compensation for CEO Venkat Nelabhotla. The board unanimously recommends voting FOR all proposals.
Vyome Holdings, Inc. will hold its 2026 Annual Meeting of Stockholders on April 15, 2026 at 12:00 p.m. Eastern Time. The Board set the record date as March 2, 2026 and disclosed 7,018,528 shares of common stock issued and outstanding as of that date.
Stockholders will vote on four proposals: (1) election of two Class II directors (Venkat Nelabhotla and John Tincoff), (2) an amendment to decrease authorized common shares from 300,000,000 to 50,000,000, (3) ratification of Kreit & Chiu CPA LLP as independent auditor, and (4) an advisory vote on executive compensation. The proxy materials and the 2025 Annual Report are being mailed in March 2026.